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In this issue of Bone Marrow Transplantation, Kurita et al. 1 describe the results of a prospective phase I/II trial of intra-bone single unit cord blood transplant (IB-CBT) in 15 patients with hematologic malignancies. Clinical outcomes were compared with 150 matched pair historic controls that received intravenous cord blood transplants (IV-CBT). Although time to neutrophil engraftment was similar between cohorts, platelet recovery occurred significantly earlier in the IB-CBT group. Other outcomes such as non-relapse mortality, relapse, survival and GvHD incidence were similar.
The central hypothesis here is intriguing. Could direct intra-osseous (IO) injection of hematopoietic stem cells (HSC) facilitate homing and expedite engraftment? The benefits of cord blood as the source of HSC are well known and include the possibility of using mismatched donors, 2 a potential increase in graft-versus-leukemia effect 3 and lower GvHD incidence. 4 The limitations include higher rates of graft failure, longer time to neutrophil and platelet recovery, and increased early transplant-related mortality. 4 Nevertheless, retrospective studies have demonstrated similar overall survival after CBT when compared to human leukocyte antigen matched unrelated donor or haplo-identical donor transplants. 5, 6 Several approaches are under investigation or have been investigated attempting to address these limitations. Controversy remains regarding the role of double CBT in adults. In the pediatric setting, however, Wagner et al. demonstrated in a randomized prospective fashion that single CBT with appropriate cell dosages (total nucleated cells42.5 × 10 7 cells/kg) lead to similar survival and transplant-related mortality with improved rates of platelet recovery and less GvHD when compared with double cord transplants. 7 Meanwhile, the feasibility of ex vivo expansion has been shown by multiple groups. [8] [9] [10] IO transplantation has intermittently been proposed by investigators in Europe and Asia as a way to minimize in vivo cell loss by direct homing, leading to improved engraftment rates. In 2008, Frassoni et al. demonstrated the feasibility of IO single CBT, with outcomes similar to those observed in historic controls that underwent double CBT. 11 Interestingly, PET imaging 1 month following IO injection revealed that FDG uptake within the iliac crest where the CB was transplanted correlated with platelet engraftment. 12 In a recent retrospective analysis, Rocha et al.
13
reviewed the European experience with IO CBT and found outcomes that were very similar to those described in the study by Kurita et al. here. 1 Brunstein et al., on the other hand, were unable to detect an IO CBT advantage in a small prospective study. The authors performed double CBT in which one unit was administered IO and one unit IV. Ten patients were treated: rates of neutrophil and platelet engraftment did not differ from historical controls.
14 Interestingly, IO co-infusion of human CD34-selected CB cells and mesenchymal stromal cells has been found to improve human hematopoietic engraftment in murine models. 15, 16 We are currently investigating this hypothesis in humans in a phase I trial (NCT02181478).
Some may say that this is too little, too late for CB-that haplo-identical transplants will replace CB for those without a matched related or unrelated donor, or even replace unrelated donor transplants. The pendulum is certainly on the haploidentical transplant side at this point. This discussion is beyond the scope of this commentary, however. For the time being, IO transplantation remains, after all these years, an enthralling idea.
